Thus, our studies do not support or discount the possibility that increasing TEX with therapy improves outcome (decreases disease activity, ACPA or rheumatoid factor levels) in RA as has been shown in T1D with teplizumab (anti-CD3) therapy (12, 13). The gene discussed is PRTN3; the disease is rheumatoid arthritis.